Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer with potent lymph node targeted immunotherapies. Elicio’s Amphiphile platform combines expertise in materials science, immunology and immuno-oncology to develop novel immunotherapies, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.
Lymph nodes: where the immune response is orchestrated
Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunotherapies in the lymph nodes, resulting in unprecedented tumor-specific immune responses and durable cures in multiple aggressive tumor models. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in 2020.
Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2020. This program consists of an Amphiphile vaccine that has the potential to elicit powerful immune responses against KRAS, a mutation found in 90% of pancreatic cancers, and 40% of colorectal cancers.
June 22, 2020 ||
Adrian Bot, MD, PhD, Named to Elicio Therapeutics Scientific Advisory Board
Elicio Therapeutics, a next generation immuno-oncology company, announced today that Adrian Bot, MD, PhD, Vice President of Translational Medicine at Kite, a Gilead Company, has joined Elicio’s Scientific Advisory Board. » Read more
April 16, 2020 ||
Elicio Therapeutics and National Cancer Institute Collaborate to Study ELI-002 mutant KRAS Targeting Mechanism
Elicio Therapeutics, a next generation immuno-oncology company, today announced that it has established a collaboration with the National Cancer Institute (NCI) to characterize T cell responses to ELI-002 in animals. » Read more
Orchestrating the immune system for precision immunity — Download this articleto see how Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.